VALGANCICLOVIR VIATRIS 450 mg clinical trials

Effectiveness of a preventive strategy for cytomegalovirus infection guided differently from a universal prophylactic strategy in kidney transplant patients - CYTOPREV

This study compares different ways to prevent cytomegalovirus (CMV) infection after a kidney transplant. It tests a specific medicine, VALGANCICLOVIR VIATRIS, to see how well it works and if it's better than standard prevention to keep patients healthy.